Chronic Kidney DiseaseNCT07179211
Peripheral Artery Disease in Regular Hemodialysis Patients
An observational study of Chronic Kidney Disease, run by Sohag University at 1 site in Egypt.
Trial summary
Recent studies have reinforced the association between high NLR and PAD in hemodialysis patients. This highlights the need for further studies to confirm its predictive value and determine optimal cut-off thresholds tailored to local patient populations. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Chronic Kidney Disease
- How many people
- 120 participants
- Where
- 1 siteEgypt
- Study dates
- 13 Jul 2025to 13 Jul 2026
- How long will I take part?
- 120 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: The present study aims to investigate the relationship between NLR and the presence of PAD in patients undergoing regular hemodialysis. By establishing this association in a well-defined population, we hope to provide evidence that supports the use of NLR as a simple, cost-effective tool for PAD risk stratification and early intervention
Who may be able to join
- Adult patients aged ≥18 years.
- Undergoing maintenance hemodialysis for at least 3 months (thrice weekly)
- Able to provide informed consent.
- Willing to undergo clinical and laboratory evaluations, including peripheral vascular assesment
Who cannot join
- Active infection or sepsis at the time of evaluation
- . Patients who have a sedimentation rate of more than 60 mm/hour
- . Known autoimmune or hematologic disorders that may influence leukocyte count.
- Current use of immunosuppressive therapy, corticosteroids, or chemotherapy.5. History of malignancy.6. Patients with incomplete medical records or unable to undergo peripheral vascular assessment.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Relation Between Neutrophil to Lymphocyte Ratio and Peripheral Artery Disease in Regular Hemodialysis Patients at Sohag University Hospital
Recent studies have reinforced the association between high NLR and PAD in hemodialysis patients. This highlights the need for further studies to confirm its predictive value and determine optimal cut-off thresholds tailored to local patient populations. Accordingly, the present study aims to investigate the relationship between NLR and the presence of PAD in patients undergoing regular hemodialysis. By establishing this association in a well-defined population, we hope to provide evidence that supports the use of NLR as a simple, cost-effective tool for PAD risk stratification and early intervention
- Conditions
- Chronic Kidney Disease
- Medical subject headings
- Renal Insufficiency, Chronic
What is being measured
The primary outcome is the main question the study is designed to answer.
The aim of this study is to evaluate the predictive value of the neutrophil-to- lymphocyte ratio (NLR) for the presence of peripheral artery disease (PAD) in patients undergoing regular hemodialysis.
Measured: 6months
% of patients with affection in neutrophills to lymphocytes ratio in parient on regular hemodialysis.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2025
- Study start13 Jul 2025
- Primary completion13 Jan 2026 (estimated)
- Study completion13 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney DiseaseStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 120 participants (estimated)
- Target duration
- 120 Months
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Islam Gamal Salem, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07179211
- Sponsor's protocol ID
- Soh-Med-25-7-19MS
- Status last verified
- Sep 2025
- First submitted
- 2 Sep 2025
- Last updated
- 17 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relation Between Neutrophil to Lymphocyte Ratio and Peripheral Artery Disease in Regular Hemodialysis Patients at Sohag University Hospital
- ClinicalTrials.gov ID
- NCT07179211
- Acronym / sponsor ID
- Soh-Med-25-7-19MS
- Conditions
- Chronic Kidney Disease
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 13 Jul 2025 (actual)
- Primary completion
- 13 Jan 2026 (estimated)
- Study completion
- 13 Jul 2026 (estimated)
- First posted
- 17 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recent studies have reinforced the association between high NLR and PAD in hemodialysis patients. This highlights the need for further studies to confirm its predictive value and determine optimal cut-off thresholds tailored to local patient populations. Accordingly, the present study aims to investigate the relationship between NLR and the presence of PAD in patients undergoing regular hemodialysis. By establishing this association in a well-defined population, we hope to provide evidence that supports the use of NLR as a simple, cost-effective tool for PAD risk stratification and early intervention
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 120 Months
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- The present study aims to investigate the relationship between NLR and the presence of PAD in patients undergoing regular hemodialysis. By establishing this association in a well-defined population, we hope to provide evidence that supports the use of NLR as a simple, cost-effective tool for PAD risk stratification and early intervention
Key inclusion criteria (4 listed)
- Adult patients aged ≥18 years.
- Undergoing maintenance hemodialysis for at least 3 months (thrice weekly)
- Able to provide informed consent.
- Willing to undergo clinical and laboratory evaluations, including peripheral vascular assesment
Key exclusion criteria (4 listed)
- Active infection or sepsis at the time of evaluation
- . Patients who have a sedimentation rate of more than 60 mm/hour
- . Known autoimmune or hematologic disorders that may influence leukocyte count.
- Current use of immunosuppressive therapy, corticosteroids, or chemotherapy.5. History of malignancy.6. Patients with incomplete medical records or unable to undergo peripheral vascular assessment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The aim of this study is to evaluate the predictive value of the neutrophil-to- lymphocyte ratio (NLR) for the presence of peripheral artery disease (PAD) in patients undergoing regular hemodialysis.
Time frame: 6months
% of patients with affection in neutrophills to lymphocytes ratio in parient on regular hemodialysis.
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Kidney Disease
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Disease, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The aim of this study is to evaluate the predictive value of the neutrophil-to- lymphocyte ratio (NLR) for the presence of peripheral artery disease (PAD) in patients undergoing regular hemodialysis. (time frame: 6months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025.